Quest Diagnostics Shatters First Quarter 2026 Expectations with Robust Revenue Growth and Upbeat Guidance
Quest Diagnostics, a leading provider of diagnostic information services, has reported a stellar first quarter 2026, exceeding expectations with impressive revenue growth and upbeat guidance for the year.
The company's strong performance reflects its focused business strategy, delivering innovative solutions that meet customers' evolving needs for lab insights. During the first quarter, Quest grew revenues by over 9%, driven almost entirely by organic revenue growth on broad-based demand for its clinical innovations, expansion into new clinical areas, and collaborations with elite healthcare and consumer health organizations.
Jim Davis, Chairman, Chief Executive Officer, and President of Quest Diagnostics, attributed the company's success to its strategic focus, saying, "Our strong first quarter performance reflects a focused business delivering innovative solutions that meet our customers' evolving needs for lab insights."
The company's growth was particularly pronounced in the physician channel, where it delivered high single-digit revenue growth on strong demand for clinical innovations, geographic expansion from greater health plan access, and increased volume from its growing business in enterprise accounts. Quest also made significant strides in end-stage renal disease, a new clinical area for the company, with revenues growing at a double-digit rate.
In the hospital channel, Quest grew revenues at a double-digit rate, driven by collaborative lab solutions for Corewell Health, a leading health system in Michigan. The company's Co-Lab solutions combine its scale, clinical depth, and operational excellence to improve quality and cost efficiencies, with implementation proceeding smoothly.
Quest's consumer channel also delivered significant revenue growth during the quarter, driven by strong demand for its clinical innovations and collaborations with top consumer health brands. The company's trusted healthcare brand enables it to drive efficient customer acquisition for its direct-to-consumer platform, Questhealth.com, which reported robust double-digit customer repeat rates and notable demand for new solutions.
The company's adjusted diluted earnings per share grew by approximately 13%, supported by productivity gains from the deployment of automation and AI across its operations. Given its strong first quarter momentum and continued strategic focus, Quest raised its revenue and EPS guidance for the year.
With a proven track record of innovation and execution, Quest Diagnostics is poised to continue its growth trajectory in 2026. As Jim Davis noted, "We are raising our revenue and EPS guidance for the year, reflecting our confidence in our strategy and ability to execute."
